Drug Patents owned by Radius Health Inc

1. List of Tymlos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748382 RADIUS HEALTH INC Method of drug delivery for bone anabolic protein
Oct, 2027

(4 years from now)

US8148333 RADIUS HEALTH INC Stable composition comprising a PTHrP analogue
Nov, 2027

(4 years from now)

US7803770 RADIUS HEALTH INC Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(8 years from now)

US10996208 RADIUS HEALTH INC Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(15 years from now)

US11255842 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
M Sep 20, 2024

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic